Malaria Research and Treatment

Malaria Research and Treatment / 2019 / Article

Retraction | Open Access

Volume 2019 |Article ID 4274315 | 1 page | https://doi.org/10.1155/2019/4274315

Retracted: Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes

Received07 Apr 2019
Accepted07 Apr 2019
Published20 Jun 2019

Malaria Research and Treatment has retracted the article titled “Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes” [1]. A part of this research was done as a Fulbright Fellowship awarded to Evehe Marie Solange and performed with funding from the US National Institutes of Health (R01 AI55604) in Professor Carol Sibley’s Laboratory at the Department of Genome Sciences, University of Washington Seattle, USA. Drs. Solange and Sibley did not approve publication and funding from the Fulbright Fellowship and the NIH was not acknowledged. The article lacked details of the methods and needs significant revisions.

References

  1. I. M. Ali, P. M. Netongo, A.-T. Barbara et al., “Amodiaquine-artesunate versus artemether-lumefantrine against uncomplicated malaria in children less than 14 years in Ngaoundere, North Cameroon: efficacy, safety, and baseline drug resistant mutations in pfcrt, pfmdr1, and pfdhfr Genes,” Malaria Research and Treatment, vol. 2013, Article ID 234683, 10 pages, 2013. View at: Publisher Site | Google Scholar

Copyright © 2019 Malaria Research and Treatment. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

453 Views | 150 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.